907 related articles for article (PubMed ID: 26165918)
1. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
[TBL] [Abstract][Full Text] [Related]
2. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children.
Collins CL; Salt P; McCarthy N; Chantler T; Lane L; Hemme F; Diggle L; Buttery J; Kitchin NR; Moxon ER; Pollard AJ
Vaccine; 2004 Oct; 22(31-32):4262-9. PubMed ID: 15474717
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
[TBL] [Abstract][Full Text] [Related]
5. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart.
Embree J; Law B; Voloshen T; Tomovici A
Clin Vaccine Immunol; 2015 Mar; 22(3):282-90. PubMed ID: 25540274
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
[TBL] [Abstract][Full Text] [Related]
8. Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV.
Gajdos V; Vidor E; Richard P; Tran C; Sadorge C
Vaccine; 2015 Jul; 33(32):3988-96. PubMed ID: 26087294
[TBL] [Abstract][Full Text] [Related]
9. Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy.
Ferrera G; Cuccia M; Mereu G; Icardi G; Bona G; Esposito S; Marchetti F; Messier M; Kuriyakose S; Hardt K
Hum Vaccin Immunother; 2012 Mar; 8(3):355-62. PubMed ID: 22327497
[TBL] [Abstract][Full Text] [Related]
10. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
[TBL] [Abstract][Full Text] [Related]
12. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine.
Sänger R; Behre U; Krause KH; Loch HP; Soemantri P; Herrmann D; Schmitz-Hauss E; Wolter J; Hoet B
Eur J Pediatr; 2007 Dec; 166(12):1229-36. PubMed ID: 17235521
[TBL] [Abstract][Full Text] [Related]
13. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of one dose of diphtheria, tetanus, acellular pertussis and poliomyelitis vaccine (Repevax®) followed by two doses of diphtheria, tetanus and poliomyelitis vaccine (Revaxis®) in adults aged ≥ 40 years not receiving a diphtheria- and tetanus-containing vaccination in the last 20 years.
Dominicus R; Galtier F; Richard P; Baudin M
Vaccine; 2014 Jun; 32(31):3942-9. PubMed ID: 24852717
[TBL] [Abstract][Full Text] [Related]
15. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial.
Scheifele DW; Halperin SA; Ochnio JJ; Ferguson AC; Skowronski DM
Pediatr Infect Dis J; 2005 Dec; 24(12):1059-66. PubMed ID: 16371866
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age.
Carlsson RM; Claesson BA; Selstam U; Fagerlund E; Granström M; Blondeau C; Hoffenbach A
Pediatr Infect Dis J; 1998 Nov; 17(11):1026-33. PubMed ID: 9849987
[TBL] [Abstract][Full Text] [Related]
18. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China.
Li RC; Li FX; Li YP; Hou QM; Li CG; Li YN; Chen FS; Hu XZ; Su WB; Zhang SM; Fang HH; Ye Q; Zeng TD; Liu TX; Li XB; Huang YN; Deng ML; Zhang YP; Ortiz E
Vaccine; 2011 Nov; 29(50):9337-44. PubMed ID: 22001281
[TBL] [Abstract][Full Text] [Related]
19. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
Tregnaghi M; Zambrano B; Santos-Lima E
Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
[TBL] [Abstract][Full Text] [Related]
20. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
Johns TL; Hutter GE
Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
